Abiopharma

🔍 Taubman Paul J (Executive)

Company: PJT Partners Inc. (PJT)

Report Date: 2026-04-30

Detailed Transactions and Holdings:

• Sold 36,000 shares of Partnership Units of PJT Partners Holdings LP (Derivative)
  Date: 2026-04-30 | Code: M | equity_swap_involved: false | shares_owned_after: 5,388,000.00 | transaction_form_type: 4 | Footnotes: F1, F2, F3, F2, F2, F4

Footnotes:

• F1: In an SEC Form 8-K filed by the Issuer on November 26, 2025, the Issuer previously disclosed that the Reporting Person intended to elect to exchange up to 36,000 Partnership Units of PJT Partners Holdings LP ("Partnership Units") in future quarterly exchange windows, including the Issuer's current quarterly exchange window. On February 26, 2026, the Reporting Person submitted an Election to Exchange 36,000 Partnership Units, with such exchange to be settled for either cash or Class A Common Stock, as determined by the Issuer's Board of Directors.
• F2: Subject to the terms of the Issuer's Exchange Agreement, on a quarterly basis, Partnership Units may be exchanged for cash or, at the election of the Issuer, shares of Class A Common Stock of the Issuer on a one-for-one basis.
• F3: Effective April 30, 2026, the Reporting Person's Partnership Units were exchanged for cash.
• F4: Includes Partnership Units that were acquired upon the occurrence of specified vesting events or grants and previously reported as Performance LTIP Units of PJT Partners Holdings LP. Of the 5,388,000 Partnership Units reported, 200,000 remain subject to a previously disclosed time-based vesting condition on March 1, 2027.